Among @ eligible patients ( @ to CP , @ to docetaxel ) , the objective response rates were @ % ( @ % confidence interval : @ % -@ % ) and @ % ( @ % confidence interval : @ % -@ % ) and median progression-free survival was @ months and @ months in the CP arm and the docetaxel arm , respectively .